Buy-side to be pressured by a raft of new derivatives regulations this year
By Ted Leveroni, chief commercial
officer at DTCC-Euroclear Global Collateral
If you’re in the
over-the-counter (OTC) derivatives market the chances are that
early 2017 is going to present some considerable challenges for
you, especially if you’re on the buy-side. Some of
the tasks will be new, some more familiar, but in all cases
they will be tackled most effectively with one eye on the
By now of course, the OTC derivatives
market is no stranger to the tactical and strategic challenges
of meeting regulatory compliance deadlines whilst getting on
with business. Since the US was first out of the blocks in
responding to the G20 reform mandate via the 2010 Dodd-Frank
Act, new rules on reporting, clearing and related processes
have become a constant presence.
This article is available to subscribers and registered users
Please log in to continue reading.
Not yet registered? Take a free trial.
If you have already taken a free trial you
have ongoing access to the analysis section of FOW.com including this story.
Log in using your details below to read.
Already have an account? |